CenterBook Partners LP Buys Shares of 4,283 Krystal Biotech, Inc. (NASDAQ:KRYS)

CenterBook Partners LP bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,283 shares of the company’s stock, valued at approximately $671,000.

Several other large investors have also modified their holdings of KRYS. Raymond James Financial Inc. acquired a new position in shares of Krystal Biotech during the fourth quarter worth about $15,989,000. Legal & General Group Plc increased its position in Krystal Biotech by 1.8% during the 4th quarter. Legal & General Group Plc now owns 69,425 shares of the company’s stock worth $10,876,000 after purchasing an additional 1,261 shares during the period. Bank of Montreal Can increased its position in Krystal Biotech by 5.7% during the 4th quarter. Bank of Montreal Can now owns 3,325 shares of the company’s stock worth $521,000 after purchasing an additional 179 shares during the period. FMR LLC raised its stake in shares of Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company’s stock worth $675,833,000 after buying an additional 21,133 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of Krystal Biotech by 1.8% in the 4th quarter. Federated Hermes Inc. now owns 13,048 shares of the company’s stock valued at $2,044,000 after buying an additional 229 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $165.00 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34. The company has a market capitalization of $4.75 billion, a price-to-earnings ratio of 55.18 and a beta of 0.75. The stock has a fifty day moving average of $173.96 and a two-hundred day moving average of $172.25.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.30 earnings per share. On average, analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on KRYS. Jefferies Financial Group assumed coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Finally, Chardan Capital upped their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $220.00.

Insider Activity

In other news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).